| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2576579 | International Congress Series | 2007 | 5 Pages |
Abstract
.In this paper a new analysis of the PROactive study is presented. If procedure-related endpoints (coronary and leg revascularisation) are excluded, the efficacy of pioglitazone in the prevention of all-cause mortality, non-fatal myocardial infarction and stroke, in high risk type 2 diabetic patients, is clearly shown by the study. As far as the safety issues are concerned, the reported increase in heart failure is most likely due to the greater incidence of edema in pioglitazone-treated patients.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Molecular Biology
Authors
Paolo Brunetti,